JWCAR 031
Alternative Names: JWCAR-031Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb; JW Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 05 Sep 2024 Preclinical trials in Small cell lung cancer in China (Parenteral) (JW Therapeutics pipeline, September 2024)
- 05 Sep 2024 Preclinical trials in Small cell lung cancer in USA (Parenteral) (JW Therapeutics pipeline, September 2024)